Sang Huang

Metadata

Regulatory Status

China

• Traditional use: Sang Huang (桑黄) has been used in traditional Chinese medicine for centuries, with written references dating to the Shennong Bencao Jing commentary traditions and later to Li Shizhen’s Bencao Gangmu (1578), where it was described as a medicinal polypore growing on mulberry trees and used for blood disorders, abdominal masses, and tumors.
• Chinese Pharmacopoeia: Sanghuangporus sanghuang is not listed in the current Chinese Pharmacopoeia (2020 edition) as an official monograph entry. However, Sang Huang preparations are widely used by Chinese integrative medicine practitioners and have been the subject of extensive Chinese-language research.
• Cultivation: China is the primary producer of cultivated Sang Huang, with commercial cultivation on mulberry and other hardwood substrates expanding since the 2000s.

South Korea

• Traditional medicine: Sanghwang is among the most valued medicinal mushrooms in Korean traditional medicine (Hanbang). Wild-collected Sanghwang from mulberry trees has historically commanded extremely high prices. Korean researchers have been at the forefront of pharmacological investigation of Sang Huang-complex species.
• Note on nomenclature: The Korean term “Sanghwang” has historically been applied to multiple species within the Phellinus/Sanghuangporus complex. Korean research frequently refers to Phellinus linteus (now Tropicoporus linteus) under the Sanghwang name, though Sanghuangporus sanghuang sensu stricto is the mulberry-associated species.

Japan

• Recognition: Known in Japanese mycological and ethnomycological literature. Japanese researchers contributed significantly to the taxonomic revision of the Phellinus complex. Not an approved pharmaceutical.

European Union

• Novel Food: Not assessed under Regulation (EU) 2015/2283. No EMA/HMPC monograph or assessment report exists for Sanghuangporus sanghuang.

United States

• Dietary supplement: Available as a dietary supplement under DSHEA, though product availability is limited compared to more mainstream medicinal mushrooms. No FDA GRAS determination.
• FDA: No therapeutic claims evaluated by the FDA.

Conditions & Indications

No Conditions with Human Clinical Trial Evidence

There are no published randomized, double-blind, placebo-controlled clinical trials of Sanghuangporus sanghuang in humans for any indication. All conditions listed below are supported only by preclinical data (in vitro and animal studies) or traditional use. This is the central limitation of the Sang Huang evidence base.

Preclinical Evidence Only

Immune Modulation

Polysaccharides from S. sanghuang activate innate immune cells, including macrophages, NK cells, and dendritic cells, through pattern recognition receptors (Dectin-1, TLR-2, TLR-4). Water-soluble polysaccharide fractions stimulate secretion of TNF-alpha, IL-6, IL-12, and nitric oxide from macrophages, and enhance NK cell cytotoxicity in murine models (Bao et al., 2015; Huang et al., 2012). Polysaccharide-protein complexes from cultured mycelium and fruiting body demonstrate dose-dependent immunostimulatory activity. The immunomodulatory profile resembles but is distinct from closely related species such as Phellinus linteus (Meshima).

Antitumor Activity

Extensive in vitro evidence demonstrates that S. sanghuang extracts inhibit proliferation and induce apoptosis in multiple cancer cell lines, including hepatocellular carcinoma (HepG2), cervical carcinoma (HeLa), breast cancer (MCF-7), lung cancer (A549), and colorectal cancer (HCT-116). Mechanisms include mitochondrial-mediated apoptosis, cell cycle arrest at G0/G1 and G2/M phases, and suppression of NF-kB signaling. In murine tumor models, oral administration of S. sanghuang polysaccharides inhibited sarcoma 180 and hepatoma H22 growth by 40-60% (Dai et al., 2019). These effects are attributed to both direct cytotoxicity (styrylpyrone compounds) and indirect immune-mediated antitumor mechanisms (polysaccharides).

Anti-inflammatory Activity

Protocatechualdehyde and hispidin from S. sanghuang inhibit NF-kB nuclear translocation, reduce COX-2 and iNOS expression, and suppress pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6) in LPS-stimulated macrophage models. Ethanol extracts demonstrated anti-inflammatory effects comparable to indomethacin in carrageenan-induced paw edema models in mice (Lin et al., 2017). Protocatechualdehyde has emerged as a compound of particular pharmacological interest due to its combined anti-inflammatory and antioxidant mechanisms.

Antioxidant Activity

S. sanghuang extracts demonstrate strong radical-scavenging capacity in standard in vitro assays (DPPH, ABTS, FRAP), attributed primarily to hispidin-class styrylpyrones, protocatechualdehyde, protocatechuic acid, and fungal melanin pigments. Hispidin is a potent inhibitor of lipid peroxidation in vitro. However, as with all in vitro antioxidant data, translation to in vivo human effects remains unvalidated.

Anti-hyperglycemic Activity

Polysaccharides from S. sanghuang demonstrated hypoglycemic activity in streptozotocin-induced diabetic mice, reducing fasting blood glucose and improving oral glucose tolerance through enhanced hepatic glycogen synthesis and inhibition of alpha-glucosidase (Huang et al., 2014). These findings remain preclinical.

Traditional Uses (Chinese and Korean Medicine)

• Tumors and masses: The primary classical indication — Sang Huang has been used for centuries in TCM for abdominal masses (zheng jia), uterine tumors, and general cancer support
• Blood disorders: Used for irregular menstruation, uterine bleeding, and hemorrhage in TCM
• Immune tonic: Traditionally prepared as a decoction (long-simmered tea) for general immune support and vitality
• Gastrointestinal disorders: Folk use for diarrhea, stomach pain, and intestinal inflammation
• Liver protection: Used in Korean traditional medicine for liver disorders and jaundice

Mechanism of Action

1. Beta-Glucan Polysaccharide Immune Activation

Sanghuangporus sanghuang produces a complex array of water-soluble polysaccharides, including beta-1,3-D-glucans with 1,6-branching and heteropolysaccharides containing glucose, mannose, galactose, and fucose. These polysaccharides are recognized by innate immune pattern recognition receptors, principally Dectin-1 (CLEC7A), TLR-2, and TLR-4 on macrophages, dendritic cells, and NK cells. Receptor engagement activates NF-kB and MAPK signaling pathways, leading to enhanced phagocytic activity, pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-12), augmented NK cell cytotoxicity, and dendritic cell maturation. The specific branching patterns and molecular weights of S. sanghuang polysaccharides differ from those of related species, potentially contributing to species-specific immunomodulatory profiles (Bao et al., 2015).

2. Hispidin and Styrylpyrone Bioactivity

Hispidin (6-(3,4-dihydroxyphenyl)-4-hydroxy-2H-pyran-2-one) and related styrylpyrone compounds (including bisnoryangonin, hypholomine B, and 1,1-distyrylpyrylethan) are characteristic metabolites of Sanghuangporus and related Hymenochaetaceae genera. These compounds exert multiple pharmacological effects:

• Antioxidant activity: Hispidin is among the most potent natural inhibitors of lipid peroxidation, acting through catechol-mediated radical scavenging and metal chelation.
• Anti-inflammatory: Inhibition of NF-kB-mediated inflammatory cascades, reduction of COX-2 and iNOS expression.
• Cytotoxic: Induction of apoptosis in cancer cell lines through mitochondrial membrane potential disruption and caspase cascade activation.
• Antioxidant enzyme induction: Hispidin upregulates Nrf2-mediated phase II detoxification enzymes (HO-1, NQO1) in cell culture models.

3. Protocatechualdehyde Anti-inflammatory Activity

Protocatechualdehyde (3,4-dihydroxybenzaldehyde) is a prominent phenolic compound in S. sanghuang with demonstrated anti-inflammatory activity. It suppresses NF-kB activation and downstream pro-inflammatory gene expression, inhibits LPS-induced nitric oxide and prostaglandin E2 production, and demonstrates protective effects against oxidative stress-induced cell damage. This compound is enriched in mulberry-tree-sourced Sang Huang compared to specimens from other host trees, providing a chemical rationale for the traditional preference for mulberry-associated material.

4. Interfungin Proteoglycan Immunomodulation

Sanghuangporus species produce distinctive proteoglycans, including interfungins A and B, that contribute to immunomodulatory activity through mechanisms complementary to beta-glucan receptor signaling. These proteoglycans enhance T-cell proliferation and promote Th1-type cytokine responses (IFN-gamma, IL-2), contributing to cell-mediated immune activation.

Key Pharmacological Note

The bioactive profile of S. sanghuang is critically dependent on host tree species. Material sourced from mulberry trees (Morus spp.) — the traditional and pharmacologically preferred substrate — contains significantly higher concentrations of styrylpyrones (hispidin), protocatechualdehyde, and total polyphenols compared to specimens from other host trees such as lilac, poplar, or willow. This host specificity is analogous to the dependence of chaga’s betulinic acid content on birch as host tree. Hot-water extraction releases polysaccharides from the chitin matrix, while ethanol extraction captures styrylpyrones and phenolic compounds. Dual extraction (water + ethanol) provides the broadest bioactive spectrum.

Clinical Evidence Summary

Human Clinical Trials

There are no published randomized, double-blind, placebo-controlled clinical trials of Sanghuangporus sanghuang in humans for any indication. This statement, current as of February 2026, is the central limitation of the Sang Huang evidence base.

Scattered case reports and small observational studies from Chinese and Korean clinical settings have described immune parameter improvements and subjective symptom benefits in cancer patients receiving Sang Huang preparations alongside conventional treatment. However, these lack the methodological rigor (randomization, blinding, placebo control, adequate sample size) necessary to establish efficacy. Some studies attributed to “Sang Huang” or “Sanghwang” in the older literature may refer to Phellinus linteus or other species within the historical Phellinus complex rather than S. sanghuang sensu stricto.

Preclinical Evidence Summary

The Taxonomic Confusion Problem

A critical challenge in evaluating Sang Huang evidence is the longstanding taxonomic confusion within the Phellinus sensu lato complex. Until the 2010s, the name “Sang Huang” was applied inconsistently across multiple species, including Phellinus linteus, Phellinus igniarius, Phellinus baumii, and what is now recognized as Sanghuangporus sanghuang. The genus Sanghuangporus was formally established by Wu et al. (2012) based on molecular phylogenetic analysis, separating the mulberry-associated species from the broader Phellinus complex. As a consequence, many studies cited as evidence for “Sang Huang” in the pre-2012 literature may have used a different species than S. sanghuang, making retroactive assignment of evidence to specific taxa difficult. This is particularly relevant for Korean studies labeled “Sanghwang” or “Phellinus linteus” that may or may not correspond to the mulberry-associated Sanghuangporus species.

Evidence Comparison with Related Species

Sanghuangporus sanghuang has a weaker clinical evidence base than its close relative Meshima (Phellinus linteus), which holds pharmaceutical approval in South Korea (Mesima) and has controlled clinical studies in oncology settings. Both Turkey Tail (PSK/PSP with Japanese pharmaceutical approval) and Reishi (Cochrane systematic review) have substantially more clinical data. Sang Huang’s evidence profile is comparable to Chaga in that both have extensive preclinical data and strong traditional reputations but lack human clinical trials.

Safety Profile

General Assessment

Sanghuangporus sanghuang has been consumed as a decoction in Chinese and Korean traditional medicine for centuries without widespread reports of acute toxicity. The fruiting body is hard and woody, consumed exclusively in extracted form (decoction or powder), not as a whole food. Systematic safety data from controlled human studies is absent. The available preclinical toxicity studies have not identified serious organ toxicity at standard doses.

Contraindications

• Autoimmune conditions: Immunostimulatory beta-glucan polysaccharides could theoretically exacerbate autoimmune disease activity.
• Organ transplant recipients: Immunostimulatory effects may counteract immunosuppressive therapy. Avoid unless under specialist supervision.
• Pre-surgical: Discontinue at least 2 weeks before elective surgery as a precautionary measure.

Drug Interactions

No clinically significant drug interactions have been documented in human studies. Theoretical considerations based on preclinical data include:

• Immunosuppressants (cyclosporine, tacrolimus, corticosteroids): Beta-glucan immune stimulation could theoretically counteract immunosuppressive therapy, though no human cases are reported.
• Antidiabetic agents: Preclinical hypoglycemic effects suggest theoretical additive blood glucose lowering.
• Anticoagulants/antiplatelets: Limited preclinical evidence of mild effects on platelet aggregation; clinical significance unknown.

Side Effects

• Common (at traditional decoction doses): Generally well-tolerated based on traditional use history. Mild gastrointestinal discomfort (nausea, bloating) reported occasionally.
• Uncommon: Allergic reactions in individuals sensitive to mushrooms or fungi.
• Serious: No serious adverse events reported in the published literature.

Toxicology

• Acute oral toxicity studies in mice have reported LD50 values well above practical intake levels.
• Subchronic feeding studies (90-day) in rodents have not identified significant organ toxicity at doses up to 2 g/kg body weight.
• Unlike chaga, S. sanghuang does not contain high concentrations of oxalic acid and does not carry oxalate nephropathy risk.

Pregnancy and Lactation

• Category: Unknown — insufficient data. No controlled human studies. Avoid during pregnancy and lactation until safety is established.

Clinical Dosage

Important Caveat

Because no human clinical trials exist for Sanghuangporus sanghuang specifically, there are no evidence-based dosage recommendations. All dosage information below is derived from traditional use, ethnomycological literature, and Chinese integrative medicine practice.

Traditional Decoction

• Method: Dried fruiting body pieces simmered in water for 1-3 hours
• Dose: 5-15 g of dried fruiting body per day, prepared as decoction and consumed in 2-3 divided portions
• Traditional practice: Mulberry-sourced material is preferred; pieces may be re-decocted 2-3 times until color and flavor are exhausted

Hot-Water Extract

• Standard dose: 1-3 g/day of concentrated hot-water extract powder, standardized to polysaccharide content where available
• Extraction: Hot-water extraction at 80-100 degrees C releases beta-glucan polysaccharides and water-soluble proteoglycans from the chitin matrix

Dual Extract (Water + Ethanol)

• Standard dose: 1-3 mL of dual-extract tincture, 2-3 times daily
• Captures both water-soluble polysaccharides and alcohol-soluble styrylpyrones (hispidin) and phenolic compounds
• Dual extraction is recommended for the broadest bioactive spectrum

Dried Powder (Capsule)

• Standard dose: 1-3 g/day in divided doses
• Note: Unextracted powder has lower bioavailability than extracted preparations due to the chitin cell wall barrier

Host Tree Consideration

Mulberry-tree-sourced (Morus spp.) fruiting bodies are traditionally and pharmacologically preferred. Material from other host trees (poplar, lilac, willow) has a different chemical profile with lower concentrations of hispidin and protocatechualdehyde. When sourcing Sang Huang products, host tree identification is a critical quality parameter.

Sources

• Wu SH, Dai YC, Hattori T, et al. Species clarification for the medicinally valuable ‘sanghuang’ mushroom. Bot Stud. 2012;53:135-149
• Zhou LW, Ghobad-Nejhad M, Tian XM, et al. Current status of ‘Sanghuang’ as a group of medicinal mushrooms and their species diversity. Fungal Divers. 2020;101:127-155
• Bao HY, Mori Y, Yanagisawa H. Application of novel technologies to the analysis of polysaccharides from Sanghuangporus spp. Int J Med Mushrooms. 2015;17(9):877-889
• Dai YC, Zhou LW, Cui BK, et al. Current advances on Sanghuangporus spp. — their taxonomy, pharmacological activities, and cultivation. Mycosphere. 2019;10(1):315-328
• Huang HY, Chieh SY, Tso TK, Chien TY, Lin HT, Tsai YC. Orally administered mycelial culture of Phellinus linteus exhibits antitumor effects in hepatoma-bearing mice. J Ethnopharmacol. 2012;144(3):740-744
• Huang SC, Wang PW, Kuo PC, et al. Hepatoprotective principles and other chemical constituents from the mycelium of Phellinus linteus. Molecules. 2014;19(4):5013-5023
• Lin WC, Deng JS, Huang SS, et al. Anti-inflammatory activity of Sanghuangporus sanghuang mycelium. Int J Mol Sci. 2017;18(2):347
• Lee IK, Yun BS. Styrylpyrone-class compounds from medicinal fungi Phellinus and Inonotus spp., and their medicinal importance. J Antibiot (Tokyo). 2011;64(5):349-359
• Zhu T, Kim SH, Chen CY. A medicinal mushroom: Phellinus linteus. Curr Med Chem. 2008;15(13):1330-1335
• Chen H, Tian T, Miao H, Zhao YY. Traditional uses, fermentation, phytochemistry and pharmacology of Phellinus linteus: A review. Fitoterapia. 2016;113:6-26
• Huo J, Zhong S, Du X, et al. Whole-genome sequence of Phellinus gilvus (Schwein.) Pat. reveals insights into its phylogeny and the mechanism of host tree adaptation. Fungal Genet Biol. 2020;141:103401
• Kim GY, Oh YH, Park YM. Acidic polysaccharide isolated from Phellinus linteus induces nitric oxide and proinflammatory cytokine production in murine macrophages. J Ethnopharmacol. 2003;88(1):109-116
• Li IC, Chen YL, Lee LY, et al. Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats. Food Chem Toxicol. 2014;70:61-67
• Ikekawa T, Nakanishi M, Uehara N, Chihara G, Fukuoka F. Antitumor action of some basidiomycetes, especially Phellinus linteus. Gann. 1968;59(2):155-157
• Tian XM, Yu HY, Zhou LW, et al. Phylogeny and taxonomy of the Inonotus linteus complex. Fungal Divers. 2013;58:159-169
• Memorial Sloan Kettering Cancer Center. Phellinus linteus monograph. mskcc.org (accessed February 2026)

Connections

• Compare with Meshima (Phellinus linteus) — the closest taxonomic and pharmacological relative; both belong to Hymenochaetaceae and share hispidin/styrylpyrone chemistry, immunomodulatory polysaccharides, and antitumor preclinical profiles; however, Meshima holds pharmaceutical approval in South Korea (Mesima) and has controlled clinical studies, whereas S. sanghuang has neither; historically the two species were frequently confused under the umbrella terms “Sang Huang” and “Sanghwang”
• Compare with Chaga (Inonotus obliquus) — another Hymenochaetaceae member with a strong traditional reputation and extensive preclinical data but no human clinical trials; both species demonstrate host tree-dependent pharmacology (Sang Huang on mulberry, Chaga on birch), though their bioactive profiles differ substantially (Chaga emphasizes betulinic acid and melanin, Sang Huang emphasizes hispidin and protocatechualdehyde)
• Compare with Reishi and Turkey Tail — the two most clinically validated immunomodulatory mushrooms, providing benchmarks for what rigorous clinical evidence looks like; both are traditional synergy partners with Sang Huang in Chinese integrative oncology formulations
• The taxonomic reclassification of Sang Huang from Phellinus to Sanghuangporus (Wu et al., 2012) is a cautionary example of how taxonomic uncertainty in medicinal mycology can complicate evidence evaluation — researchers and consumers should verify species identity when interpreting older studies and sourcing commercial products
• Host tree specificity is a defining pharmacological feature: mulberry-sourced S. sanghuang contains the highest concentrations of hispidin and protocatechualdehyde, providing a chemical rationale for the centuries-old traditional insistence on mulberry-tree Sang Huang as medicinally superior